title: Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer.
abstract: BACKGROUND
  DNA ploidy analysis has been investigated as a prognostic indicator in prostate cancer. Most of the data is derived from retrospective studies using paraffin-embedded tissue. This method has drawbacks related to the quality of DNA histograms and uncontrolled data collection.
  
  
  METHODS
  DNA ploidy analysis of freshly resected prostatic tissue was prospectively compared with conventional prognostic variables in 97 men treated with radical prostatectomy for localized prostate cancer.
  
  
  RESULTS
  Regarding the patients, 31.9% were African American and 66% had pathologic Stages C or D1 disease. Only 9.6% of patients with Stages A2 and B had a prostate-specific antigen (PSA) value greater than 10 ng/ml, whereas 97% of patients with PSA values greater than 20 ng/ml had pathologic Stages C and D1. PSA levels correlated with Gleason score (P = < 0.05); 51% and 100% of patients with Gleason score 5-7 and 8-10, respectively, had PSA values greater than 10 ng/ml. Twenty-two patients (23%) had DNA aneuploid tumors. Comparisons of mechanical to enzymatic cell suspensions indicated that DNA aneuploidy was better preserved in mechanical cell preparations. DNA ploidy correlated with pathologic stage (P = < 0.05) and Gleason score (P = < 0.05). Fifteen of 79 patients (18.9%) with Gleason score 5-7 had DNA aneuploid tumors versus 71.4% of patients with Gleason score 8-10. PSA groups correlated with ploidy status (P = 0.01). Although the majority of patients (19 of 22) with DNA aneuploid tumors had elevated preoperative PSA levels, none had a PSA value greater than 50 ng/ml.
  
  
  CONCLUSIONS
  DNA ploidy analysis correlated with established prognostic indicators in prostate cancer; however, its independent correlation with natural history and treatment outcome must be established for it to have an effect on therapeutic decisions.
authors.affiliation: Division of Hematology/Oncology, Veterans Administration Medical Center, Allen Park, MI 48101.
authors.forename: M H
authors.initials: MH
authors.lastname: Hussain
authors.forename: I
authors.initials: I
authors.lastname: Powell
authors.forename: N
authors.initials: N
authors.lastname: Zaki
authors.forename: Z
authors.initials: Z
authors.lastname: Maciorowski
authors.forename: W
authors.initials: W
authors.lastname: Sakr
authors.forename: M
authors.initials: M
authors.lastname: KuKuruga
authors.forename: D
authors.initials: D
authors.lastname: Visscher
authors.forename: G P
authors.initials: GP
authors.lastname: Haas
authors.forename: J E
authors.initials: JE
authors.lastname: Pontes
authors.forename: J F
authors.initials: JF
authors.lastname: Ensley
mesh_terms: D000368:Aged; D000782:Aneuploidy; D004273:DNA, Neoplasm / Q000032:analysis*; D004171:Diploidy; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D011467:Prostate / Q000737:chemistry* / Q000276:immunology / Q000601:surgery; D017430:Prostate-Specific Antigen / Q000032:analysis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000601:surgery
chemical_list: D004273:DNA, Neoplasm; D017430:Prostate-Specific Antigen